DGAP-News: SYGNIS AG: GBC Research publishes Update on

DGAP-News: SYGNIS AG / Key word(s): Research Update SYGNIS AG: GBC Research publishes Update on 31.10.2013 / 11:48 --------------------------------------------------------------------- Press Release GBC Research publishes Update on Successful Completion of SYGNIS AG Capital Increase - Capital increase strengthens liquidity and finances further growth - Break-even expected in 2014 - Buy rating and target price of EUR 4.35 per share confirmed Madrid/Heidelberg, 31 October 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange), the DNA amplification and sequencing company, announced today that GBC Research, a German independent research house focusing on listed small, and midcap companies, has published a research update following the successful completion of the Company's capital increase as of October 28, 2013. With gross proceeds of EUR 2.7 million GBC sees the Company well financed to drive its operating business and further growth. The subscription price was EUR 2.65 per share. New shares that were not subscribed in the course of the rights offering by existing shareholders were offered to selected German and international institutional investors in a private placement at a purchase price equivalent to the subscription price. In the transaction 1,019,309 new shares were subscribed against cash. GBC forecasts that the transaction provides the Company with the financial flexibility needed to further execute on its business plans and closes the gap to break-even expected in 2014. GBC confirmed the target price valuation of EUR 4.35 per share. The fair value of the Company was determined on the basis of a DCF model, taking into account the capital increase (post money). GBC's total valuation of the Company is now at EUR 45 million, an increase compared with the initial valuation in July of EUR 42.6 million. In light of the current price level of 2.71 (XETRA closing price on 28/10/2013), GBC also confirmed their BUY rating. For further information please contact: <pre> SYGNIS AG Pilar de la Huerta CEO/CFO Tel: +34-918063089 Email: pdelahuerta@sygnis.es </pre> About SYGNIS AG: www.sygnis.com After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi(R) and is currently developing other products in the field of Next Generation Sequencing. ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### End of Corporate News --------------------------------------------------------------------- 31.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: SYGNIS AG Im Neuenheimer Feld 515 69120 Heidelberg Germany Phone: 06221 454-6 Fax: 06221 454-700 E-mail: contact@sygnis.de Internet: www.sygnis.de ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 237156 31.10.2013